Products for Research Use Only
RegisterLogin

Mupirocin (lithium)

CAT: 0804-HY-W108875-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W108875-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae) . Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis[1][2][3][4][5][6].
CAS Number
73346-79-9
Product Name Alternative
BRL-4910A (lithium) ; Pseudomonic acid (lithium)
UNSPSC
12352005
Hazard Statement
H317
Target
Aminoacyl-tRNA Synthetase; Antibiotic; Bacterial
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection; Endocrinology
Assay Protocol
https://www.medchemexpress.com/mupirocin-lithium.html
Purity
97.0
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)
Smiles
O[C@@H]1[C@@](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O[Li])=O)=O)[C@@H]1O)([H])C[C@H]2[C@@]([C@@H](C)[C@@H](O)C)([H])O2
Molecular Formula
C26H43LiO9
Molecular Weight
506.56
Precautions
H317
References & Citations
[1]Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27 (4) :495-8.|[2]Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6 (10) :761-70.|[3]Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42 (3) :272-5.|[4]Twilley D, et al. Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes. Front Pharmacol. 2022 Apr 11;13:862112. |[5]Ha KR, et al. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope. 2008 Mar;118 (3) :535-40. |[6]Gilbart J, et al. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother. 1993 Jan;37 (1) :32-8.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 4

Related Products

CatalogName
HY-B0958-01Mupirocin
HY-B0958AMupirocin (calcium)
HY-B0958R-01Mupirocin (Standard)
HY-N7068-01Mupirocin (calcium hydrate)
HY-N7068RMupirocin (calcium hydrate) (Standard)
HY-137674BIsoGTP (lithium)
HY-134891HMBPP (lithium)
HY-W250163-01NAD+ (lithium)
HY-B1128B-01Cefamandole (lithium)
HY-B1680-01Lithium citrate

Alternative Products

CatalogName
574480Mupirocin Lithium
BIL9900-01Lithium mupirocin
M023-100MGMupirocin lithium salt
B4872-5.1Mupirocin

Popular Products